Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is positioned for positive revenue growth driven by its expanding oncology portfolio and strong performance in existing therapeutic areas, particularly HIV. The anticipated approval and launch of Trodelvy in the metastatic triple-negative breast cancer segment, along with a significant increase in payer coverage, highlight Gilead's commitment to diversifying its revenue streams. Additionally, projected sales growth from key products such as Livdelzi, along with continued strong performance in the HIV franchise and the PrEP market, underscores the company's operational efficiency and potential for sustained financial success moving forward.

Bears say

Gilead Sciences has experienced a significant reduction in projected revenues, notably lowering its FY25 Veklury revenue guidance from $1.4 billion to $1.0 billion, with a further decline anticipated for 2026, which is forecasted at $600 million. The company’s cell therapy franchise has shown a continuous revenue decline of 6% year-over-year, and a 10% decrease is expected in 2026, attributed to competitive pressures within the sector. Additionally, Gilead is facing policy-related headwinds and declining sales from its antiviral products, further suggesting a negative outlook for the company’s financial health moving forward.

Gilead Sciences (GILD) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 16 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $150.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $150.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.